source
- Delays in reaching clinical proof-of-concept can dramatically increase biotech cash burnThe article explains how the timing of achieving clinical proof‑of‑concept (POC) directly affects a biotech company's cash consumption. While a study’s cost is important, the ongoing expenses of st…
- Merck says 2027 will focus on pipeline and new product launches despite recent trial winsMerck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth. Th…